58.03
전일 마감가:
$57.07
열려 있는:
$56.54
하루 거래량:
274.64K
Relative Volume:
0.73
시가총액:
$2.01B
수익:
-
순이익/손실:
$-91.00M
주가수익비율:
-15.81
EPS:
-3.67
순현금흐름:
$-74.38M
1주 성능:
-1.59%
1개월 성능:
+9.55%
6개월 성능:
+5.86%
1년 성능:
+35.43%
Disc Medicine Inc Stock (IRON) Company Profile
명칭
Disc Medicine Inc
전화
(617) 674-9274
주소
321 ARSENAL STREET, SUITE 101, WATERTOWN
IRON을(를) 다른 주식과 비교
주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
---|---|---|---|---|---|---|
![]()
IRON
Disc Medicine Inc
|
58.03 | 2.04B | 0 | -91.00M | -74.38M | -3.67 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
366.54 | 98.88B | 11.42B | 3.64B | 3.50B | 13.99 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
563.00 | 58.84B | 14.21B | 4.46B | 3.56B | 39.68 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
438.93 | 56.12B | 2.46B | -319.09M | -52.09M | -2.47 |
![]()
ARGX
Argen X Se Adr
|
661.83 | 41.20B | 3.05B | 1.28B | -614.78M | 19.58 |
![]()
ONC
Beone Medicines Ltd Adr
|
288.18 | 35.49B | 3.81B | -644.79M | -669.77M | -6.24 |
Disc Medicine Inc Stock (IRON) Upgrades & Downgrades
날짜 | 액션 | 분석자 | 등급 변경 |
---|---|---|---|
2025-07-21 | 개시 | Truist | Buy |
2025-07-03 | 재개 | Morgan Stanley | Overweight |
2025-06-11 | 재개 | Raymond James | Strong Buy |
2025-02-27 | 개시 | TD Cowen | Buy |
2024-11-05 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
2024-11-04 | 업그레이드 | Raymond James | Outperform → Strong Buy |
2024-10-23 | 개시 | Jefferies | Buy |
2024-10-16 | 개시 | Scotiabank | Sector Outperform |
2024-08-22 | 개시 | Wells Fargo | Overweight |
2024-04-01 | 다운그레이드 | Raymond James | Strong Buy → Outperform |
2023-12-19 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
2023-06-09 | 업그레이드 | Raymond James | Outperform → Strong Buy |
2023-06-07 | 개시 | H.C. Wainwright | Buy |
2023-05-17 | 개시 | Raymond James | Outperform |
2023-04-28 | 개시 | Cantor Fitzgerald | Overweight |
2023-04-21 | 개시 | Stifel | Buy |
2023-04-20 | 개시 | Morgan Stanley | Overweight |
2023-03-23 | 개시 | BMO Capital Markets | Outperform |
2023-02-28 | 개시 | SVB Securities | Outperform |
모두보기
Disc Medicine Inc 주식(IRON)의 최신 뉴스
Disc Medicine Reports Q2 2025 Financial Results and Clinical Progress - TipRanks
Disc Medicine (IRON) Q2 Loss Widens 109% - AOL.com
Disc Medicine: Strong Financial Position and Promising Drug Pipeline Justify Buy Rating - TipRanks
Disc Medicine Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Disc Medicine Misses On Losses But Keeps Wall Street Optimistic - Finimize
Disc Medicine Stumbles On Earnings But Analysts Stay Bullish - Finimize
Disc Medicine (IRON) Q2 Loss Widens 109% - The Motley Fool
Disc Medicine Shares Fall After Wider-Than-Expected Q2 Loss - MarketScreener
Disc Medicine reports Q2 EPS ($1.58), consensus ($1.14) - TipRanks
Disc Medicine, Inc. SEC 10-Q Report - TradingView
Disc Medicine Earnings: FDA Filing Timeline Set for EPP Drug as Cash Reserves Hit $650M Milestone - Stock Titan
How strong is Disc Medicine Inc. company’s balance sheetInvest confidently with real-time market updates - Jammu Links News
Is Disc Medicine Inc. a good long term investmentDiscover dynamic stocks ready to soar - Jammu Links News
Is it the right time to buy Disc Medicine Inc. stockMarket-leading growth rates - Jammu Links News
What catalysts could drive Disc Medicine Inc. stock higher in 2025Achieve consistent double-digit growth - Jammu Links News
What analysts say about Disc Medicine Inc. stockMaximize portfolio growth with professional advice - Jammu Links News
Is Disc Medicine Inc. a growth stock or a value stockMarket-beating performance - Jammu Links News
Published on: 2025-08-03 11:24:58 - Jammu Links News
What are analysts’ price targets for Disc Medicine Inc. in the next 12 monthsBuild a winning investment strategy today - Jammu Links News
How many analysts rate Disc Medicine Inc. as a “Buy”Realize exceptional returns through smart trading - Jammu Links News
How does Disc Medicine Inc. generate profit in a changing economyHigh-octane investment opportunities await - Jammu Links News
Insider Selling at Disc Medicine Inc.: A Signal or a Symptom? - AInvest
Is Disc Medicine Inc. stock overvalued or undervaluedLow Risk Report For Consistent Profits - Jammu Links News
Institutional Investors in Disc Medicine, Inc. (NASDAQ:IRON) See US$140m Decrease in Market Cap Last Week, Although Long-term Gains Have Benefitted Them. - 富途牛牛
Why Disc Medicine Inc. stock attracts strong analyst attentionNews Based Entry Opportunity Alerts Detected - metal.it
Morgan Stanley Assumes Coverage of Disc Medicine (IRON) With $85 PT - MSN
How does Disc Medicine Inc. compare to its industry peersExpert Picks Watchlist For 2025 - Jammu Links News
Disc Medicine's NDA Submission for Bitopertin in EPP: A High-Probability Catalyst for Value Creation - AInvest
Disc Medicine, Inc. (IRON) Set to Submit NDA for Bitopertin in October 2025 - Insider Monkey
What is the dividend policy of Disc Medicine Inc. stockMaximize gains with strategic stock entries - Jammu Links News
Are Investors Undervaluing Disc Medicine, Inc. (NASDAQ:IRON) By 49%? - Yahoo Finance
How volatile is Disc Medicine Inc. stock compared to the marketBreakneck growth rates - jammulinksnews.com
Published on: 2025-07-28 05:56:42 - Jammu Links News
Should I hold or sell Disc Medicine Inc. stock in 2025Invest smarter with real-time trading signals - Jammu Links News
When is the best time to buy Disc Medicine Inc. stockWatchlist Winner Update - metal.it
Is Disc Medicine Inc. stock a growth or value play2x Return Forecast - metal.it
Insider Selling at Disc Medicine Inc.: A Balancing Act Between Portfolio Strategy and Investor Sentiment - AInvest
Can Disc Medicine Inc. stock recover from recent declineSuperior profit margins - Jammu Links News
Disc Medicine Inc (IRON) 재무 분석
매출
순이익
현금흐름
주당 순 이익
자본화:
|
볼륨(24시간):